Navigation Links
Isis Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Date:10/15/2010

CARLSBAD, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 17th Annual NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 11:00 a.m. ET at the Millennium Broadway Hotel & Conference Center in New York.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 23 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
2. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
3. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
4. Prolong Pharmaceuticals Secures $30 Million in Funding
5. Amylin Pharmaceuticals to Webcast Third Quarter Results
6. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
7. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
8. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
9. Reportlinker Adds Sales Force Effectiveness in Pharmaceuticals - Cost Pressures Increase Pharmaceutical Companies Adoption of New Sales Models and Technologies
10. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
11. Jazz Pharmaceuticals Receives FDA Complete Response Letter Regarding JZP-6 for Treatment of Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... N.C. , Oct. 17, 2014 ... the Medical Affairs function has come across several ... resources efficiently and managing globalization.  ... Practices, LLC is dedicated to providing benchmarking and ... Medical Affairs Consortium is a service composed of ...
(Date:10/17/2014)... Oct. 17, 2014  Hanger, Inc. (NYSE: ... its results of operations for the quarter ended September ... market closes.  A conference call to discuss these results ... Friday, November 7, 2014. Those wishing to participate should ... November 14, 2014 by dialing 1-855-859-2056 and referencing Conference ...
(Date:10/17/2014)... UBM Medica US announces that Neurology Times ... for neurologists and other healthcare providers, features special coverage on ... discussions of the latest developments in approaches to diagnosis. ... , more than the total of those who have multiple ... can be difficult because there are no confirmatory medical tests. ...
Breaking Medicine Technology:Early Key Findings from the Medical Affairs Consortium Research 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 2Neurology Times Features Coverage of Parkinson and Alzheimer Disease 3
... Repligen Corporation,(Nasdaq: RGEN ) announced today that ... to evaluate the use of RG1068, synthetic human ... by magnetic resonance,imaging (MRI). This Phase 3 study ... approximately 250 patients will receive an,unenhanced MRI followed ...
... First-in-Class Treatment for Type 2 Diabetes -, ... company focused on the discovery and development of,proprietary ... today that it has dosed the first cohort ... of MBX-2982, a potential first-in-class treatment,for type 2 ...
Cached Medicine Technology:Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 2Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 3Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging 4Metabolex Initiates Phase 1 Trial of MBX-2982 2
(Date:10/20/2014)... (PRWEB) October 20, 2014 Principle Business ... takes pride in manufacturing top-of-the-line absorbent products. The ... of its most popular brand, Tranquility® Premium Protection absorbent ... a new website, gave its packaging a new look, ... the brand message to the public. , The new ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
(Date:10/20/2014)... 20, 2014 Punzoné , the first ... U.S., has a lot to celebrate this month. October marks ... the achievements and contributions of Americans of Italian heritage and ... and today it shares its favorite Italian cocktails and encourages ... Italy - even if it is only in a glass. ...
(Date:10/19/2014)... 20, 2014 Recently, BambooIndustry.com, one of ... its new range of bamboo deckings . Moreover, ... natural items; they are now available at deeply discounted ... it is hard to overstate the significance of online ... to online services. The company’s workers are striving to ...
(Date:10/19/2014)... 2014 Recently, Fancyflyingfox.com, an innovative company ... has announced its latest designs of 2014 mother ... new elegant outfits are offered with big discounts, up ... before October 30 can enjoy this special offer. ... strategies, it has become one of the leading brands ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... By Steven Reinberg HealthDay Reporter , ... reports of potentially hazardous food products were filed with ... first seven months of operation, the U.S. Food and ... requires manufacturers, processors, packers and distributors to immediately report ...
... , WEDNESDAY, July 28 (HealthDay News) -- A certain type ... disease and other neurological disorders, new research confirms. ... people violently act out their dreams during the rapid eye ... and related neurological disorders as much as a half century ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, July ... rheumatoid arthritis at bay, possibly because it dampens the ... may also protect people who already have the autoimmune ... actually isn,t a new concept. There have been other ...
... new study of mental health status and the use of ... Policy Research found that nearly one in five adults in ... needed help for a mental or emotional health problem. ... than 1 million, reported symptoms associated with serious psychological distress ...
... HealthDay Reporter , TUESDAY, July 27 (HealthDay News) -- The ... their 40s is due more to the technology itself than ... study. For years, experts have known that mammography,s performance ... and they,ve placed much of the blame on the notion ...
... heterosexual men,s hostility, while heterosexual men, gay men and ... Dr. Scott Keiller from Kent State University at Tuscarawas ... due to women,s unparalleled potential for gratifying, or frustrating, ... gatekeepers in men,s quests for sexual pleasure, patriarchal power ...
Cached Medicine News:Health News:FDA Cites Its Food Safety Web Site 2Health News:Sleep Disorder May Help Predict Parkinson's Decades Earlier 2Health News:Sleep Disorder May Help Predict Parkinson's Decades Earlier 3Health News:Could Drinking Help Thwart Rheumatoid Arthritis? 2Health News:Could Drinking Help Thwart Rheumatoid Arthritis? 3Health News:Nearly 1 in 5 Californians report need for mental health services, study finds 2Health News:Technology May Explain Mammogram's Poorer Performance in Younger Women 2Health News:Technology May Explain Mammogram's Poorer Performance in Younger Women 3Health News:A man with attitude 2
Freedom Cath® is a latex, self-adhering, one-piece catheter designed for everyday wear....
The Freedom Clear® LS Long Seal is a 100% latex-free, self-adhering, one piece catheter with an ultra-thin sheath for everyday wear. Its long seal provides added security....
The UltraFlex® all silicone self-adhering male external catheter is 100% latex-free and eliminates the risk of latex-related skin irritations. This breathable catheter promotes healthy skin and i...
Used as a percutaneous entry needle to introduce wire guides. The coaxial design reduces potential A.V. malformations. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: